ArticleAntimicrobial agents and chemotherapy2003
Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.
Article in Antimicrobial agents and chemotherapy, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 145 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
145 citing papers in PubMed, 354 citations in OpenAlex.
- Ciprofloxacin dosage and emergence of resistance in human commensal bacteria.The Journal of infectious diseases · 2009Trial
- NGS-Based Genomic Characterization of ESBL/AmpC-Producing Extraintestinal PathogenicAntibiotics (Basel, Switzerland) · 2026Article
- Marine Antimicrobial Peptide as a Promising Alternative to Polymyxin B.Marine drugs · 2026Article
- Integrated conjugative elements drive the formation of pandemic clones of Escherichia coli with hybrid chromosomes.Molecular biology and evolution · 2026Article
- Genomic Characterisation of Pyometra-AssociatedAntibiotics (Basel, Switzerland) · 2026Article
- Consequences of benzalkonium chloride tolerance for selection dynamics and de novo resistance evolution driven by antibiotics.npj antimicrobials and resistance · 2026Article
- Clinical Usefulness of Early Evaluation of the Bacteriological Effect of Antibiotics Administered as Empiric Therapy Using the Fully Automated Urine Particle Analyzer UF-5000 in Febrile Urinary Tract Infections.International journal of urology : official journal of the Japanese Urological Association · 2025Article
- Fitness seascapes are necessary for realistic modeling of the evolutionary response to drug therapy.Science advances · 2025Article
- Rapid and Integrated Bacterial Evolution Analysis unveils gene mutations and clinical risk of Klebsiella pneumoniae.Nature communications · 2025Article
- Characterisation of Antimicrobial Resistance in Special-Fed Veal Production Environments.Zoonoses and public health · 2025Article
- Insights into antibiotic resistance promoted by quinolone exposure.Antimicrobial agents and chemotherapy · 2025Article
- Fluoroquinolone-specific resistance trajectories in E. coli and their dependence on the SOS-response.BMC microbiology · 2025Article
- Article
- The complex development of psoralen-interstrand crosslink resistance inbioRxiv : the preprint server for biology · 2024Article
- Acidic Urine pH and Clinical Outcome of Lower Urinary Tract Infection in Kidney Transplant Recipients Treated with Ciprofloxacin and Fosfomycin.Antibiotics (Basel, Switzerland) · 2024Article
- Clonal and resistance profiles of fluoroquinolone-resistant uropathogenicFrontiers in microbiology · 2024Article
- Tracing the Evolutionary Pathways of Serogroup O78 Avian PathogenicAntibiotics (Basel, Switzerland) · 2023Article
- Comparison of Antibacterial Activity of Phytochemicals against Common Foodborne Pathogens and Potential for Selection of Resistance.Microorganisms · 2023Article
- Chance Favors the Prepared Genomes: Horizontal Transfer Shapes the Emergence of Antibiotic Resistance Mutations in Core Genes.Molecular biology and evolution · 2023Article
- A CcdB toxin-derived peptide acts as a broad-spectrum antibacterial therapeutic in infected mice.EMBO reports · 2023Article
85 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli strains from patients with uncomplicated urinary tract infections were examined by DNA sequencing for fluoroquinolone resistance-associated mutations in six genes: gyrA, gyrB, parC, parE, marOR, and acrR. The 54 strains analyzed had a susceptibility range distributed across 15 dilutions of the fluoroquinolone MICs. There was a correlation between the fluoroquinolone MIC and the number of resistance mutations that a strain carried, with resistant strains having mutations in two to five of these genes. Most resistant strains carried two mutations in gyrA and one mutation in parC. In addition, many resistant strains had mutations in parE, marOR, and/or acrR. No (resistance) mutation was found in gyrB. Thus, the evolution of fluoroquinolone resistance involves the accumulation of multiple mutations in several genes. The spontaneous mutation rate in these clinical strains varied by 2 orders of magnitude. A high mutation rate correlated strongly with a clinical resistance phenotype. This correlation suggests that an increased general mutation rate may play a significant role in the development of high-level resistance to fluoroquinolones by increasing the rate of accumulation of rare new mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.